Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetics of drug‐induced liver injury: Current knowledge and future prospects
Ann K. Daly
Clinical and Translational Science (2022) Vol. 16, Iss. 1, pp. 37-42
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Hepatic immune regulation and sex disparities
Patrizia Burra, Alberto Zanetto, Bernd Schnabl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 6
Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use
Rolf Teschke, Gaby Danan
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10855-10855
Open Access | Times Cited: 14
Drug‐Induced Liver Injury with Commonly Used Antibiotics in the All of Us Research Program
Shaopeng Gu, Govarthanan Rajendiran, Kennedy Forest, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 2, pp. 404-412
Open Access | Times Cited: 13
Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method
Rolf Teschke, Gaby Danan
Medicines (2024) Vol. 11, Iss. 4, pp. 9-9
Open Access | Times Cited: 4
Molecular docking to investigate HLA-associated idiosyncratic drug reactions
Kejun Li, Volker M. Lauschke, Yitian Zhou
Drug Metabolism Reviews (2025), pp. 1-34
Open Access
Genetic Variants of GBP4: Reduced Risks for Drug‐Induced Acute Liver Failure in Non‐Finnish European Population
Tsung‐Jen Liao, Menghang Xia, Paul H. Hayashi, et al.
Liver International (2025) Vol. 45, Iss. 2
Closed Access
Perspective: How complex in vitro models are addressing the challenges of predicting drug-induced liver injury
Katrina A. Taylor, R. Ram, Lorna Ewart, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Drug-Induced Liver Injury—Pharmacological Spectrum Among Children
Bianca Raluca Maris, Alina Grama, Tudor Lucian Pop
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2006-2006
Open Access
Hepatic Safety Considerations in the Use of Ulipristal Acetate for Symptomatic Uterine Fibroids
Annika Semmler, Maria E de Lange, Joost P.H. Drenth, et al.
Therapeutics and Clinical Risk Management (2025) Vol. Volume 21, pp. 367-382
Open Access
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Camilla Stephens, M. Isabel Lucena, Raúl J. Andrade
Elsevier eBooks (2025)
Closed Access
DILI prediction in drug development: present and future
Jack Uetrecht
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-12
Closed Access
In silico modeling-based new alternative methods to predict drug and herb-induced liver injury: A review
Hyun Kil Shin, Ruili Huang, Minjun Chen
Food and Chemical Toxicology (2023) Vol. 179, pp. 113948-113948
Open Access | Times Cited: 10
Idiosyncratic DILI and RUCAM under One Hat: The Global View
Rolf Teschke, Gaby Danan
Livers (2023) Vol. 3, Iss. 3, pp. 397-433
Open Access | Times Cited: 7
Idiosyncratic Adverse Drug Reactions
Alastair Mak, Jack Uetrecht
Elsevier eBooks (2024)
Closed Access | Times Cited: 2
The clinical application of genetic testing in DILI, are we there yet?
Matthew S. Krantz, Madeline Marks, Elizabeth J. Phillips
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Methods for causality assessment of idiosyncratic drug‐induced liver injury
Miren García‐Cortés, Gonzalo Matilla‐Cabello, M. Isabel Lucena
Liver International (2024)
Open Access | Times Cited: 2
Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet
Mi Lucena, Marina Villanueva-Paz, Ismael Álvarez‐Álvarez, et al.
Pharmacological Research (2023) Vol. 200, pp. 107046-107046
Open Access | Times Cited: 4
Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment
Jiayi Ma, Einar S. Björnsson, Naga Chalasani
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 239-257
Closed Access | Times Cited: 1
Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury
Huanyu Wu, Wanping Yan, Ke Liu, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 9, pp. 102472-102472
Closed Access | Times Cited: 1
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs
Ayako Suzuki, MinjunChen
Liver International (2024)
Open Access | Times Cited: 1
Relevance of Pharmacogenomics to the Safe Use of Antimicrobials
Ann K. Daly
Antibiotics (2023) Vol. 12, Iss. 3, pp. 425-425
Open Access | Times Cited: 3
Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury
Fang Cheng, Chaochao Qiu, Xiangao Jiang, et al.
Pharmacogenomics (2023) Vol. 25, Iss. 1, pp. 21-28
Closed Access | Times Cited: 2
İlaca Bağlı Karaciğer Hasarı
Melek AKİNCİ
(2023)
Open Access
Idiosyncratic DILI: Immunology in Cases with Evidence Based on RUCAM
Rolf Teschke
Journal of Modern Medicinal Chemistry (2023) Vol. 11, pp. 1-10
Open Access
Page 1 - Next Page

Scroll to top